Antihypertensive effects of the calcium antagonistic agent nifedipine. 1982

K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue

The calcium antagonist nifedipine (Adalat) was administered to 60 patients with essential hypertension and investigations were performed on acute and chronic hypotensive effects. The following results were obtained: 1. Acute hypotensive effects: Nifedipine (20 mg) was either orally or sublingually administered. Following oral administration, significant hypotensive effect was attained 20 min after administration and the maximum hypotensive response was obtained 2-4 h after administration. In cases of sublingual administration, significant hypotensive effect was notable 5 min after administration and blood pressure reached the lowest level 2-3 h after administration. The hypotensive effects lasted for a relatively longer period and significantly lower blood pressure than the control level was observed even 3 h after administration. 2. Chronic hypotensive effects: Nifedipine (30-60 mg/d) was orally administered consecutively. Significant hypotensive effect was attained in and after the 4th week of administration. The yearly changes in the long-term administration cases over 3 years demonstrated significant hypotensive effects. The cases who did not respond to single administration of thiazides or beta-blockers exhibited significant hypotensive response by the combined use of nifedipine. 3. Change in heart rate: In the acute study, heart rate increased after nifedipine administration and lasted for several hours. In the long-term administration cases, the changes in heart rate were not significant. 4. Side effects attributable to nifedipine such as headache in 2 cases, facial flushing, palpitation, warm sensation and nausea in 1 case each were observed early after the administration but there were no cases in whom administration was discontinued due to these side effects.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
December 1978, Clinical science and molecular medicine. Supplement,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
May 1979, Circulation,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
May 1979, The American journal of medicine,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
July 1985, Acta pharmacologica et toxicologica,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
July 1981, Japanese circulation journal,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
November 1975, Acta pharmacologica et toxicologica,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
January 1982, Arzneimittel-Forschung,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
April 1978, Naunyn-Schmiedeberg's archives of pharmacology,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
February 1991, Journal of cardiovascular pharmacology,
K Maeda, and C Tanaka, and Y Tsukano, and H Minamikawa, and H Komatsu, and K Kotsumi, and E Inoue
June 1984, Nutrition reviews,
Copied contents to your clipboard!